

Appl. No. : 10/063,699  
Filed : May 8, 2002

### **AMENDMENTS TO THE SPECIFICATION**

**Please amend the title as follows:**

~~SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS~~  
ENCODING THE SAME A NUCLEIC ACID UNDER-EXPRESSED IN MELANOMA

**Please amend the application to include the paper copy of the Sequence Listing submitted herewith.**

**Please amend paragraph 237, beginning at page 40, as follows:**

--"Carriers" as used herein include pharmaceutically acceptable carriers, excipients, or stabilizers which are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically acceptable carrier is an aqueous pH buffered solution. Examples of physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEEN<sup>TM</sup> (a polyoxyethylene (20) sorbitan available from ICI Americas, Inc., Bridgewater, NJ), polyethylene glycol (PEG), and PLURONICS<sup>TM</sup> (a copolymer of propylene oxide and ethylene oxide available from BASF Corporation, Mount Olive, NJ).--

**Please amend paragraph 337, beginning at page 93, as follows:**

--The PRO polypeptides described herein may also be employed as therapeutic agents. The PRO polypeptides of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the PRO product hereof is combined in admixture with a pharmaceutically acceptable carrier vehicle. Therapeutic formulations are prepared for storage by mixing the active ingredient having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate,

**Appl. No.** : 10/063,699  
**Filed** : May 8, 2002

### **DELETION OF INVENTORS**

Please correct the inventorship under 37 CFR §1.48(b) by removing the following inventors from the present application:

Dan L. Eaton, Ellen Filvaroff, Mary E. Gerritsen, and Colin K. Watanabe.